About cue biopharma inc - CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
CUE At a Glance
Cue Biopharma, Inc.
40 Guest Street
Boston, Massachusetts 02135
| Phone | 1-617-949-2680 | Revenue | 9.29M | |
| Industry | Biotechnology | Net Income | -40,674,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 69.162% | |
| Fiscal Year-end | 12 / 2025 | Employees | 41 | |
| View SEC Filings |
CUE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.611 |
| Price to Book Ratio | 3.851 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.218 |
| Enterprise Value to Sales | 5.149 |
| Total Debt to Enterprise Value | 0.186 |
CUE Efficiency
| Revenue/Employee | 226,512.195 |
| Income Per Employee | -992,048.78 |
| Receivables Turnover | 9.828 |
| Total Asset Turnover | 0.198 |
CUE Liquidity
| Current Ratio | 1.836 |
| Quick Ratio | 1.836 |
| Cash Ratio | 1.641 |
CUE Profitability
| Gross Margin | 74.696 |
| Operating Margin | -447.863 |
| Pretax Margin | -437.967 |
| Net Margin | -437.967 |
| Return on Assets | -86.798 |
| Return on Equity | -149.033 |
| Return on Total Capital | -154.214 |
| Return on Invested Capital | -129.224 |
CUE Capital Structure
| Total Debt to Total Equity | 50.723 |
| Total Debt to Total Capital | 33.653 |
| Total Debt to Total Assets | 27.573 |
| Long-Term Debt to Equity | 5.732 |
| Long-Term Debt to Total Capital | 3.803 |